Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01544114 · ClinicalTrials.gov registry record · Phase 4
A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
A Phase 4 study of Juvenile Idiopathic Arthritis (JIA), sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 46
- Enrollment target
- 17
- Study locations
NCT01544114 is a Phase 4 study of Juvenile Idiopathic Arthritis (JIA) that has completed, run by Amgen. The registered enrollment target is 46 participants. The trial reports 17 study locations across 13 states.
The verdict
NCT01544114, a Phase 4 study of Juvenile Idiopathic Arthritis (JIA), has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 46 participants
- Enrollment target
- 17
- Study locations
Study Summary
A 6-month study of the safety of VIMOVO in adolescents aged 12 to 16 years with JIA.
Conditions Studied
Interventions
- DRUG VIMOVO 250/20
- DRUG VIMOVO 375/20
- DRUG VIMOVO 500/20
Study Locations (17)
New York
- Research Site - Brooklyn
- Research Site - New Hyde Park
- Research Site - New York
Ohio
- Research Site - Cincinnati
- Research Site - Cleveland
- Research Site - Toledo
Arkansas
- Research Site - Little Rock
California
- Research Site - San Francisco
Colorado
- Research Site - Aurora
District of Columbia
- Research Site - Washington D.C.
Florida
- Research Site - West Palm Beach
Georgia
- Research Site - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01544114
The ClinicalTrials.gov registry entry for NCT01544114 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Juvenile Idiopathic Arthritis (JIA) appearing as the primary indexed condition, and to 3 interventions - of which VIMOVO 250/20 is the first listed.
NCT01544114 reports 17 study locations spanning 13 distinct geographic areas - top geographies include New York, Ohio, Arkansas.
Frequently Asked Questions
What is clinical trial NCT01544114 about?
NCT01544114 is a clinical study titled "A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)". A 6-month study of the safety of VIMOVO in adolescents aged 12 to 16 years with JIA.
What is the current status of trial NCT01544114?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2012-04. Estimated completion is 2015-02.
What conditions does trial NCT01544114 study?
This clinical trial studies the following conditions: Juvenile Idiopathic Arthritis (JIA).
What interventions are being tested in trial NCT01544114?
The interventions under investigation include: VIMOVO 250/20 (DRUG), VIMOVO 375/20 (DRUG), VIMOVO 500/20 (DRUG).
Who is sponsoring clinical trial NCT01544114?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01544114 being conducted?
This trial has 17 study locations across Arkansas, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Juvenile Idiopathic Arthritis (JIA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.